A call to ARMs: The promise of immunomodulatory small molecules

Expert Review of Clinical Pharmacology

Volumn 6, Issue 3, 2013, Pages 223-225

  Spiegel, David A ^a,b  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antibody; antibody recruiting molecules; immunomodulator; immunotherapy; small molecule; synthetic immunology

Indexed keywords

ANTIBODY RECRUITING MOLECULE; BISPECIFIC ANTIBODY; MONOCLONAL ANTIBODY; SMALL MOLECULE TRANSPORT AGENT; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN PRESENTING CELL; BREAST METASTASIS; CELL KILLING; CELL MEMBRANE PERMEABILITY; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG TARGETING; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; REVIEW; THERMOSTABILITY;

BIOPHARMACEUTICS; HUMANS; IMMUNOLOGIC FACTORS; MOLECULAR STRUCTURE; MOLECULAR WEIGHT;

EID: 84877615286     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.13.10     Document Type: Review

References (20)

1. Walsh G. Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 28(9), 917-924 (2010).
2. Goodman M. Market watch: sales of biologics to show robust growth through to 2013. Nat. Rev. Drug Discov. 8(11), 837 (2009).
3. Reichert JM. Marketed therapeutic antibodies compendium. MAbs 4(3), 413-415 (2012).
4. Reichert JMWhich are the antibodies to watch in 2013? MAbs 5(1), 1-4 (2013).
5. Murad JP, Lin OA, Espinosa EV, Khasawneh FT. Current and experimental antibodybased therapeutics: insights, breakthroughs, setbacks and future directions. Curr. Mol. Med. 13(1), 165-178 (2013).
6. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2(10), 750-763 (2002).
7. Leon JA, Goldstein NI, Fisher PB. New approaches for the development and application of monoclonal antibodies for the diagnosis and therapy of human cancer. Pharmacol. Ther. 61(1-2), 237-278 (1994).
8. Presta LG. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv. Drug Deliv. Rev. 58(5-6), 640-656 (2006).
9. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 6(9), 714-727 (2006).
10. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45(12), 2615-2623 (2002).
11. Christiansen J, Rajasekaran AK. Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol. Cancer Ther. 3(11), 1493-1501 (2004).
12. Waltz E. GlaxoSmithKline cancer drug threatens Herceptin market. Nat. Biotechnol. 23(12), 1453-1454 (2005).
13. Wurch T, Pierré A, Depil S. Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept. Trends Biotechnol. 30(11), 575-582 (2012).
14. McEnaney PJ, Parker CG, Zhang AX, Spiegel DA. Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease. ACS Chem. Biol. 7(7), 1139-1151 (2012).
15. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 23(9), 1137-1146 (2005).
16. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 6(9), 714-727 (2006).
17. Carlson CB, Mowery P, Owen RM, Dykhuizen EC, Kiessling LL. Selective tumor cell targeting using low-affinity, multivalent interactions. ACS Chem. Biol. 2(2), 119-127 (2007).
18. Huang H, Lai JY, Do J et al. Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin. Cancer Res. 17(5), 1001-1011 (2011).
19. Kodadek T. Protein binding: antibody surrogates click into place. Nat. Chem. 1(3), 183-185 (2009).
20. Oyelaran O, McShane LM, Dodd L, Gildersleeve JC. Profiling human serum antibodies with a carbohydrate antigen microarray. J. Proteome Res. 8(9), 4301-4310 (2009).